cd19/baff-r in vivo car-t cell intravenous infusion
CAR T Cell Therapy
Qi dengCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the CAR T Cell Therapy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Mb-Cart2019.1 Miltenyi Biomedicine GmbH | Phase 2 | B |
HUMAN PERIPHERAL BLOOD LEUKOCYTES The First Affiliated Hospital of Soochow University | Phase 2 | B |
Anti-Cd19/Cd22 Car-T Cells The First Affiliated Hospital of Soochow University | Phase 2 | B |
cd33-car-t cell infusion Qi deng | Phase 1 | CC |
Same molecule, other indications
cd19/baff-r in vivo car-t cell intravenous infusion is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →